Propranolol use inversely linked to melanoma recurrence

Propranolol use inversely linked to melanoma recurrence

(HealthDay)—For patients with melanoma, use of propranolol is associated with reduced risk of recurrence, according to a study published online Sept. 28 in JAMA Oncology.

Vincenzo De Giorgi, M.D., from the University of Florence in Italy, and colleagues conducted a prospective study involving melanoma treated with propranolol for off-label use. Patients with histologically confirmed stage IB and IIIA cutaneous melanoma and no evidence of metastases were asked to take propranolol as an off-label adjuvant treatment at the time of diagnosis. If they accepted, they were considered part of the propranolol cohort (19 patients); those who refused treatment but agreed to participate in the control group were considered part of the nonpropranolol cohort (34 patients).

The researchers found that the use of propranolol at the time of diagnosis was significantly inversely linked to melanoma recurrence after adjustment for known prognostic factors, with about an 80 percent reduction in risk for users (hazard ratio, 0.18).

"These results confirm recent observation that β-blockers protect patients with thick cutaneous melanoma from ," the authors write. "Repurposing the vast arsenal of approved drugs with a nononcology primary purpose may prove an attractive and inexpensive strategy for offering more effective treatment options to patients with cancer."


Explore further

Propranolol use tied to increased mortality in child-pugh B, C

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: JAMA Oncology

Copyright © 2017 HealthDay. All rights reserved.

Citation: Propranolol use inversely linked to melanoma recurrence (2017, September 29) retrieved 16 January 2022 from https://medicalxpress.com/news/2017-09-propranolol-inversely-linked-melanoma-recurrence.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
31 shares

Feedback to editors